Gottlieb Q&A: Off-Label Communications And Right-To-Try

US FDA Commissioner nominee favors making up-to-date, accurate information available to patients and providers, but will that translate to more freedom for sponsor communications?

Scott Gottlieb admitted to not being fully briefed on the US FDA's off-label communications issues, but seems interested in policy tilting toward more information disclosure on drug uses.

The nominee for FDA Commissioner indicated in answers to written questions submitted by members of the Senate Health, Education, Labor...